Liquidia (NASDAQ:LQDA) Director Sells $7,935,561.54 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 111,049 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $71.46, for a total transaction of $7,935,561.54. Following the transaction, the director directly owned 1,065,135 shares of the company’s stock, valued at approximately $76,114,547.10. This trade represents a 9.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Liquidia Trading Up 3.5%

NASDAQ LQDA opened at $71.07 on Friday. The company has a market capitalization of $6.32 billion, a PE ratio of 507.68 and a beta of 0.58. The company has a fifty day moving average of $52.44 and a 200 day moving average of $42.03. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $73.22. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue was up 4187.1% on a year-over-year basis. Research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on LQDA. Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday, June 5th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. HC Wainwright upped their price objective on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Finally, Wells Fargo & Company raised their price objective on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.29.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Liquidia during the 4th quarter worth about $25,000. Covestor Ltd increased its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at about $34,000. Finally, NewEdge Advisors LLC acquired a new position in Liquidia in the 2nd quarter worth about $25,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).